Dishman Carbogen Amcis Share Price Today | Stock Price & Dishman Carbogen Amcis Share Screener
As of November 18, 2026, the live Dishman Carbogen Amcis share price (NSE: DCAL) is ₹121.15 on NSE and ₹121.25 on BSE, down 7.05% from the previous close, with shares trading between ₹120.01 and ₹132.95 in today's trading session, and a 52-week range of ₹121.15–₹264.95. Track Dishman Carbogen Amcis marketcap in USD to gauge the company's total market size. Use the Dishman Carbogen Amcis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dishman Carbogen Amcis opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹868 and net income of ₹22, with EBITDA of ₹178, an operating margin of 19.0% and a profit margin of 2.5%.
Dishman Carbogen Amcis Share Price Chart
Track the current stock price of Dishman Carbogen Amcis with an interactive chart. Analyse DCAL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dishman Carbogen Amcis stock quote in one place.
The quote of ₹121.15 sits between the 52-week low of ₹121.15 and the 52-week high of ₹264.95, and the latest session moved -7.05% from the previous close.
Dishman Carbogen Amcis Company Profile - Fundamental Screener
Screen Dishman Carbogen Amcis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DCAL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE385W01011.
Company Details
Classification
Identifiers and Leadership
Dishman Carbogen Amcis Balance Sheet Screener
Screen DCAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹11,923, up from ₹9,999 in 2025.
Latest statistics put total assets at ₹11,923 and shareholder funds at ₹6,677, with a leverage ratio of 0.44.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 11,923 | 9,999 | 9,581 | 9,454 | 8,638 | 8,366 | 8,200 | 7,329 | 7,177 | 6,593 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 8,076 | 7,055 | 6,724 | 6,188 | 5,773 | 5,698 | 5,678 | 5,098 | 5,066 | 4,852 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2,929 | 2,243 | 1,399 | 1,845 | 1,669 | 1,377 | 916 | 751 | 891 | 786 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 6,677 | 5,832 | 5,628 | 5,810 | 5,549 | 5,699 | 5,715 | 5,379 | 5,107 | 4,814 |
| Share Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 32 | 32 | 0 |
| Reserves & Surplus | 6,646 | 5,800 | 5,596 | 5,778 | 5,518 | 5,668 | 5,684 | 5,347 | 5,075 | 4,814 |
Dishman Carbogen Amcis Income Statement Screener - Profit & Revenue Analysis
Screen Dishman Carbogen Amcis income statement and profit fundamentals. Analyze DCAL quarterly results. Dishman Carbogen Amcis reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹868 and net profit was ₹22, equal to earnings per unit of ₹1.39, at an operating margin of 19%.
In that period expenses were ₹690, interest cost ₹43 and tax ₹24. The next period listed, 2026-Jun, shows revenue of ₹696 and net profit of ₹-58.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 868 | 696 | 511 | 724 | 733 | 661 | 727 | 662 | 525 | 796 | 690 | 625 | 730 | 595 | 657 |
| Expenses | 690 | 619 | 461 | 575 | 570 | 504 | 607 | 595 | 500 | 645 | 542 | 613 | 602 | 529 | 610 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 178 | 77 | 50 | 149 | 163 | 157 | 120 | 67 | 25 | 151 | 148 | 13 | 128 | 66 | 47 |
| Operating Profit % | 19.00% | 9.00% | 9.00% | 20.00% | 19.00% | 23.00% | 16.00% | 9.00% | 4.00% | 18.00% | 21.00% | 1.00% | 17.00% | 10.00% | 6.00% |
| Depreciation | 89 | 91 | 90 | 79 | 81 | 84 | 84 | 85 | 71 | 72 | 72 | 76 | 70 | 75 | 80 |
| Interest | 43 | 37 | 40 | 42 | 43 | 42 | 46 | 31 | 32 | 37 | 49 | 24 | 29 | 28 | 33 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 46 | -51 | -81 | 28 | 39 | 31 | -10 | -49 | -78 | 42 | 27 | -88 | 30 | -36 | -66 |
| Tax | 24 | 7 | -14 | -15 | 15 | -35 | 3 | 21 | 0 | 9 | 22 | -17 | 13 | 5 | -7 |
| Net Profit | 22 | -58 | -67 | 43 | 23 | 65 | -13 | -70 | -78 | 33 | 5 | -71 | 17 | -41 | -60 |
| EPS | 1.39 | -3.69 | -4.26 | 2.75 | 1.49 | 4.16 | -0.83 | -4.46 | -4.95 | 2.11 | 0.30 | -4.51 | 1.08 | -2.61 | -3.80 |
Dishman Carbogen Amcis Cash Flow Screener - Liquidity Fundamentals
Screen DCAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹492, and net cash flow was an inflow of ₹447.
Over the same period, investing activities used ₹245 and financing activities provided ₹201.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 492 | 371 | 379 | 266 | 355 | 513 | 585 | 282 | 226 | 303 |
| Investing Activities | -245 | -192 | -225 | -494 | -619 | -380 | -442 | -169 | -297 | -107 |
Financing and Net Cash | ||||||||||
| Financing Activities | 201 | -102 | -22 | 250 | 130 | -11 | -98 | -102 | 78 | -137 |
| Net Cash Flow | 447 | 77 | 132 | 22 | -133 | 122 | 46 | 11 | 7 | 59 |
Dishman Carbogen Amcis Shareholding Pattern Screener
See Dishman Carbogen Amcis shareholding pattern with promoter, FII, and DII holdings. Check Dishman Carbogen Amcis promoter holding and ownership changes for DCAL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 59.32%, foreign institutions 7.45%, domestic institutions 1.63% and the public 27.20%, spread across 49,009 shareholders.
The shareholder count was 49,009 in 2026-Mar, compared with 49,430 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
Institutional Investors | ||||||||
| FII Holding | 7.45% | 6.86% | 6.97% | 9.49% | 9.93% | 8.07% | 7.66% | 8.70% |
| DII Holding | 1.63% | 2.07% | 1.66% | 1.26% | 1.27% | 1.37% | 1.27% | 2.37% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 27.20% | 27.32% | 27.71% | 25.31% | 25.36% | 26.84% | 27.31% | 25.17% |
| Other Holding | 4.40% | 4.43% | 4.35% | 4.62% | 4.11% | 4.39% | 4.44% | 4.45% |
| Shareholder Count | 49,009 | 49,430 | 49,048 | 50,757 | 49,744 | 49,455 | 48,481 | 50,656 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dishman Carbogen Amcis. Dishman Carbogen Amcis dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.20 | 0.37% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹1.20 | 0.37% |
Dishman Carbogen Amcis Stock Index Membership - Nifty & Sensex
See which indices include Dishman Carbogen Amcis stock. Check DCAL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 5 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.
Complete Index List
Dishman Carbogen Amcis Market Events Screener - Corporate Actions
Get Dishman Carbogen Amcis corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dishman Carbogen Amcis stock events that may affect DCAL share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.
It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-13 | 2026-11-13 | Quarterly Result Announcement | NA | 15.37% |
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -7.86% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 2.83% |
| 2026-06-19 | 2026-06-19 | Extraordinary General Meeting | NA | -14.68% |
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | 6.64% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 5.52% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.26% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | 4.48% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -0.79% |
| 2025-05-21 | 2025-05-21 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.73% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -2.51% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -4.79% |
| 2017-03-27 | 2017-03-27 | Change Of Name | NA | - |
Dishman Carbogen Amcis Competitors Screener - Peer Stocks Comparison
Screen DCAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,347 | 40.80 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 295,413 | 87.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 176,738 | 85.00 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 126,520 | 89.90 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 120,189 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,845 | 41.80 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,220 | 39.50 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,276 | 47.90 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,188 | 25.80 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 89,226 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Dishman Carbogen Amcis Company Announcements - News & Reports Screener
Screen DCAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated November 17, 2026 and November 15, 2026.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - | |
| 2026-11-17 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-15 | Board Meeting Outcome for Unaudited Financial Results And Statutory Auditors Limited Review Report For The Second Quarter And Half Year Ended On 30/09/2026. | - |
| 2026-11-15 | Unaudited Financial Results And Statutory Auditors Limited Review Report For The Second Quarter And Half Year Ended On 30/09/2026. | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-11-04 | Board Meeting Intimation for Considering Taking On Record And Approving The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2026 | - |
| 2026-10-30 | Disclosure under Regulation 30A of LODR | - |
| 2026-10-29 | Disclosure under Regulation 30A of LODR | - |
| 2026-10-15 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-07 | Board Meeting Outcome for (I) ISSUE OF SENIOR SECURED RATED LISTED TRANSFERABLE REDEEMABLE TAXABLE NCD AGGREGATING UP TO RS. 38 CRORES (Ii) MODIFICATION/AMENDMENT IN SECURITY IN RESPECT OF NCD AGGREGATING TO ?15 CRORE HAVING SCRIP CODE 978230 | - |
| 2026-10-02 | Board Meeting Intimation for Considering And Approving (A) Fund Raising And (B) Modification/Change In Security In Respect Of NCD Having Scrip Code 978230 | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-28 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-09-24 | Closure of Trading Window | - |
| 2026-09-12 | Disclosure Pursuant To Regulations 30 And 51 Of SEBI (LODR) Regulations 2015: The CompanyS Wholly Owned Subsidiary CARBOGEN AMCIS AG Successfully Completed US FDA Inspection At Its Manufacturing Site Located At Vionnaz Switzerland Without Any Observations | - |
| 2026-09-07 | ANNUAL GENERAL MEETING AND E-VOTING NOTICE - NEWS PAPER ADVERTISEMENT | - |
| 2026-09-05 | SUBMISSION OF NOTICE OF 19TH ANNUAL GENERAL MEETING ALONGWITH ANNUAL REPORT FOR THE FINANCIAL YEAR 2025-26 AS PER REGULATIONS 34 AND 53 OF SEBI (LODR) REGULATIONS 2015 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹121.15, within a 52-week range of ₹121.15 to ₹264.95. The P/E ratio is -18.90 and the P/B ratio is 0.33, with earnings per unit of ₹6.22. Market capitalisation stands at ₹2,057.93 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.